84176-77-2

Usage

Uses

Used in Pharmaceutical Research:
1-Benzyl-4-phenylpiperidine-4-methylamine is used as a research chemical for studying its psychoactive effects and potential applications in the development of medications for neurological and psychiatric disorders. Its action as a reuptake inhibitor for neurotransmitters such as dopamine, norepinephrine, and serotonin makes it a subject of interest for research into the treatment of conditions like depression, ADHD, and Parkinson's disease.
Used in Regulatory and Control Measures:
Due to its psychoactive effects and potential for abuse, 1-benzyl-4-phenylpiperidine-4-methylamine is used as a target for regulation and control in many countries. Authorities and healthcare professionals monitor and regulate its use and distribution to mitigate the serious health risks associated with its consumption, including addiction and overdose.

InChI:InChI=1/C19H24N2/c1-3-7-17(8-4-1)15-21-16-19(11-13-20-14-12-19)18-9-5-2-6-10-18/h1-10,20-21H,11-16H2

Upstream product

• 56243-25-5 1-benzyl-4-cyano-4-phenylpiperidine 
• 40481-13-8 4-phenyl-4-cyanopiperidine 
• 98-88-4 benzoyl chloride 

Downstream Products

• 873403-64-6 (4-phenyl-[4]piperidylmethyl)-urea 
• 1071866-00-6 1,1-dimethylethyl {[4-phenyl-1-(phenylmethyl)-4-piperidinyl]methyl}carbamate 
• 847614-98-6 C₂₁H₂₃F₃N₂O 
• 266341-44-0 1-N-Benzyl-4-phenyl-4-(3-(2-methoxyphenyl)-3-oxo-2-azaprop-1-yl)piperidine 
• 1013329-87-7 1-((1-benzyl-4-phenylpiperidin-4-yl)methyl)-4-methylpiperazine 
• 761355-17-3 (4-phenylpiperidin-4-yl)methanamine 
• 7152-05-8 N-(1-benzyl-4-phenyl-[4]piperidylmethyl)-acetamide 
• 83898-31-1 (1-benzyl-4-phenyl-[4]piperidylmethyl)-carbamic acid ethyl ester 
• 873403-55-5 (1-benzyl-4-phenyl-[4]piperidylmethyl)-urea 

Relevant academic research and scientific papers

Aryl spiro compound containing formamidine as well as preparation method and application of aryl spiro compound

The invention belongs to the field of medicinal chemistry, and particularly relates to an aryl spiro compound containing formamidine as well as a preparation method and application of the aryl spiro compound. The invention relates to three aryl spiro compounds as shown in general formulas I-III and pharmaceutically acceptable salts, enantiomers, non-isomers, tautomers, solvates, polymorphic substances or prodrugs thereof. On the basis that SHP099 is used as a lead compound, a brand new compound with guanidyl at the tail end is prepared, and the problems that an existing SHP2 inhibitor is single in structural framework and the like are solved. The aryl spiro compound has the important significance of providing many modification sites and providing a basis for later structural modification. Meanwhile, the embodiment of the invention proves that the compound has an allosteric inhibition effect on SHP2 phosphatase, and a skeleton support is provided for subsequent development of an SHP2 phosphatase inhibitor.

RENIN INHIBITORS

Described are compounds which bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.

THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS

The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's disease

Heterocyclic potassium channel inhibitors

The present invention relates to a class of heterocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.

Platelet aggregation inhibiting and anticoagulant effects of oligoamines, I: N-(4-piperidinyl)methanamines

In concentrations of some μmol/l, 4-aminomethyl-4-phenylpiperidines suitably aralkylated at position 1 inhibit the platelet aggregation induced by collagen. The most potent compound 10 shows an IC50 of 5.5 · 106 mol/l. The metabolism of arachidonic acid in platelets remains unchanged. At a concentration of 10-4 mol/l 10 also depresses the fibrin formation induced by thromboplastin to 25 percent of normal.